글로벌 위암 치료제 시장 – 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 위암 약물 시장

위암 치료제 시장은 2021년에서 2028년까지의 예측 기간 동안 14.95%의 시장 성장을 목격할 것으로 예상됩니다. Data Bridge Market Research의 위암 치료제 시장 보고서는 예측 기간 내내 만연할 것으로 예상되는 다양한 요인에 대한 분석과 통찰력을 제공하고 시장 성장에 미치는 영향을 제공합니다. 전 세계적으로 위암 유병률이 증가함에 따라 위암 치료제 시장 성장이 가속화되고 있습니다.

위암은 위암이라고도 하며, 위 내벽에 암세포가 형성되면서 시작되는 암의 한 유형입니다. 이 암은 일반적으로 느리게 진행됩니다. 소화불량, 속쓰림, 가벼운 메스꺼움, 식욕 부진 등이 이 암의 초기 증상으로 간주됩니다. 종양이 진행됨에 따라 구토, 눈이나 피부가 노랗게 변함, 복통, 위 부기, 체중 감소, 변비, 대변에 혈액이 섞이는 등 증상이 악화됩니다.

전 세계 인구 중 림프종, 선암, 위장관 기질 종양, 카르시노이드 종양 의 유병률이 증가하는 것은 위암 약물 시장 성장을 주도하는 주요 요인 중 하나입니다. 담배와 알코올의 만성 소비와 고지방, 매운 음식, 단백질 섭취 감소, 신체 활동 부족과 같은 건강에 해로운 라이프스타일 채택은 위암 약물 시장 성장을 가속화합니다. 암 치료 센터의 증가와 복합 요법의 가용성은 위암 약물 시장에 더 많은 영향을 미칩니다. 또한, 의료 시스템 개선, 인구 증가, 의료 지출 증가, 연구 프로젝트에 대한 투자 급증은 위암 약물 시장에 긍정적인 영향을 미칩니다. 나아가, 연구 개발 활동과 치료 혁신을 포함하여 2021년에서 2028년까지의 예측 기간 동안 위암 약물 시장 참여자에게 수익성 있는 기회를 확대합니다. 

On the other hand, high cost associated with the treatments and lack of sufficient financial support from health insurance policies are the factors expected to obstruct the gastric cancer drug market growth. Patent expiry from many companies and introduction of generic drugs are projected to challenge the gastric cancer drug market in the forecast period of 2021-2028.

This gastric cancer drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on gastric cancer drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Gastric Cancer Drug Market Scope and Market Size

The gastric cancer drug market is segmented on the basis of type, treatment type, drug type, route of administration and end- users. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications. 

• On the basis of type, the gastric cancer drug market is segmented into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor and others.
• On the basis of treatment type, the gastric cancer drug market is segmented into chemotherapy, targeted therapy, immunotherapy, surgery, radiation therapy, medication and others.
• On the basis of drug type, the gastric cancer drug market is segmented into doxorubicin hydrochloride, sunitinib mitomycin, imatinib, fluorouracil, trastuzumab and others.
• On the basis of route of administration, the gastric cancer drug market is segmented into oral and injectable.
• On the basis of end- users, the gastric cancer drug market is segmented into hospitals, homecare, specialty clinics and others.

Global Gastric Cancer Drug Market Country Level Analysis

The gastric cancer drug market is analyzed and market size insights and trends are provided by country, type, treatment type, drug type, route of administration and end-users as referenced above.      

The countries covered in the global gastric cancer drug market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the gastric cancer drug market due to the rising prevalence of stomach cancer and the availability of advanced technology in cancer research and treatment centers.

The country section of the gastric cancer drug market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The gastric cancer drug market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for gastric cancer drug market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on gastric cancer drug market. The data is available for historic period 2011-2019.      

Competitive Landscape and Gastric Cancer Drug Market Share Analysis

The gastric cancer drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to gastric cancer drug market.

위암 약물 시장 보고서에서 다루는 주요 기업으로는 mugene Limited, Otsuka Pharmaceuticals Co., Ltd, Immutep, F. Hoffmann-La Roche Ltd, Merck KGaA, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Sanofi SA, Amgen Inc., Bayer AG, Celgene Corporation, Gilead Sciences, Inc., AstraZeneca, Ipsen Pharma, Takeda Pharmaceutical Company Limited, Samumed, LLC, Arbutus Biopharma, ASLAN Pharmaceuticals 등이 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA), 남미에 대해 개별적으로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-37307